A gradual acceptance among physicians has been observed in adopting quality care initiatives that provide cost-saving, improved patient experience in cancer care, noted Kerin Adelson, MD, of Smilow Cancer Hospital at Yale New Haven/Yale Cancer Center.
Over time, a gradual acceptance among physicians has been observed in adopting quality care initiatives that provide cost-saving, improved patient experience in cancer care, said Kerin Adelson, MD, associate professor, chief quality officer, and deputy chief medical officer for Smilow Cancer Hospital at Yale New Haven/Yale Cancer Center.
Transcript
AJMC®: How has the reception to quality care initiatives among physicians evolved over time?
Dr Adelson: So, I think that there has been a gradual acceptance that data is honest and that we all have to sort of look at the data and incorporate that into evaluation of our practice. I think for many, many years, the doctor knew best, and to some extent may still, but there was initial resistance to imposing practice standards on somebody's individual practice, that they were the advocate for their patient and outside standards may not sort of reflect the doctor-patient relationship or may even get in the way of it.
I think that there is gradual understanding that evidence-based medicine matters, that the data about how we practice is actually relevant to the care that we give and to the cost of care, and that overutilization is both costly and can actually harm the patient experience by increasing the burden of care or the treatment burden on a patient.
So, I think that sort of the sweet spot is the idea that patients don't want to spend all their time in a CAT scanner if they don't need to, and they don't want to spend all their time getting procedures that could be avoided. So, it is understanding that sometimes appropriate utilization will both save money and improve patient experience–where the alignment occurs–and that is sort of the selling point, I think, for quality initiatives.
Neurologists Share Tips for Securing Patient Access to Gene Therapies
March 19th 2025Tenacious efforts at every level, from the individual clinician to the hospital to the state to Congress, will be needed to make sure patients can access life-saving gene therapies for neuromuscular diseases.
Read More
Frameworks for Advancing Health Equity: Trans and Gender Diverse Health Care
June 28th 2024Charlie Borowicz, manager of trans and gender diverse health at Allegheny Health Network, shares how the program offers comprehensive patient-first care to those in the LGBTQ+ and gender diverse community.
Listen
EMBARK Data Show Continued Improvements With DMD Gene Therapy
March 19th 2025Data from the EMBARK trial of delandistrogene moxeparvovec in patients with Duchenne muscular dystrophy (DMD) show that benefits in functional outcomes, gene expression, and muscle imaging persist 2 years after receiving the gene therapy.
Read More
How Access to SMA Treatment Varies Globally and by Insurance Type
March 18th 2025Posters presented at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference show that therapeutic advances in treating spinal muscular atrophy (SMA) are not uniformly making it into the hands of patients who could benefit.
Read More